Program
CTX460
A development code.
Its studies are mostly in alpha 1-Antitrypsin Deficiency, led by CRISPR Therapeutics.
Furthest: phase 2, since Sep 21, 20261 company-led study, 1 open or runningNext primary completion: Jun 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CRISPR Therapeutics | 11 open or running | phase 2since Sep 21, 2026 | Sep 21, 2026 | Jun 2030phase 2 · NCT07850076 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 21, 2026First study: phase 2 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT07850076 · 68 planned · Australia
Ahead
- Jun 2030Primary completion: phase 2 study in alpha 1-Antitrypsin DeficiencyNCT07850076
TargetBeta
SERPINA1 →read by rule
“Official Title: A Phase 1/2 Multicenter, Open-label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460, a Lipid Nanoparticle Formulation of SyNTase Editing Components for In Vivo Editing of the Serine Protease Inhibitor A1 (SERPIN…”study text, by rule · the study
Other programs on SERPINA1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ensitrelvirrule | Shionogi | phase 3 | 5 |
| efdoralprin alfa | Sanofi | phase 2 | 2 |
| Proteasome Inhibitor SHY-ONC6rule | shy-therapeutics | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07850076alpha 1-Antitrypsin Deficiency · Australia | 2 | Recruiting | Jun 2030 | 68 |
How it is read
Names in the registry
- “CTX460”, 1 entry
Codes read as this program: CTX460.
Conditions, from the studies’ own filings
- alpha 1-Antitrypsin Deficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.